Literature DB >> 28927063

microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer.

Aijun Yang1, Xuenan Wang1, Chunna Yu1, Zhenzhen Jin1, Lingxia Wei2, Jinghe Cao1, Qin Wang1, Min Zhang1, Lin Zhang1, Lei Zhang3,4, Cuifang Hao5.   

Abstract

Ovarian cancer is one of the most common types of gynecological malignancy worldwide, and is the fourth leading cause of cancer-associated mortality among women. Despite improvements in therapeutic treatments, the prognosis for epithelial ovarian cancer (EOC) remains poor, mainly due to the rapid growth and metastasis of ovarian cancer tumors. An increasing number of studies have indicated that microRNAs (miRNAs) are involved in the carcinogenesis and progression of human cancer, suggesting that miRNAs may be used in clinical prognosis and as a therapeutic target in EOC. The aim of the present study was to investigate the expression levels of miRNA-494 in EOC tissues and cell lines. The clinical significance of miRNA-494 in patients with EOC was also evaluated. The results demonstrated that miRNA-494 was significantly downregulated in EOC tissues and cell lines. Low expression levels of miRNA-494 were associated with poor prognostic features, including International Federation of Gynecology and Obstetrics stage, tumor size and lymph node metastasis. In vitro functional studies demonstrated that overexpression of miRNA-494 inhibited proliferation, migration and invasion in EOC cells. By contrast, knockdown of miRNA-494 enhanced cell growth, migration and invasion in EOC cells. Notably, sirtuin 1 (SIRT1) was identified as a direct target of miRNA-494 in EOC. Furthermore, MTT, cell migration and invasion assays verified that EOC cell proliferation, migration and invasion were completely restored with forced miRNA-494 expression and SIRT1 restoration. Together, these findings suggest that miRNA-494 is a potential prognostic marker, and may provide novel therapeutic regimens of targeted therapy for EOC.

Entities:  

Keywords:  metastasis; microRNA-494; ovarian cancer; prognostic; sirtuin 1

Year:  2017        PMID: 28927063      PMCID: PMC5588040          DOI: 10.3892/ol.2017.6501

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  47 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  siRNA and miRNA for the treatment of cancer.

Authors:  R Jankovic; S Radulovic; M Brankovic-Magic
Journal:  J BUON       Date:  2009-09       Impact factor: 2.533

3.  MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1.

Authors:  Ying Shi; Jianjun Huang; Jun Zhou; Ying Liu; Xiaodan Fu; Yimin Li; Gang Yin; Jifang Wen
Journal:  Oncol Rep       Date:  2015-05-19       Impact factor: 3.906

4.  miR‑494 is an independent prognostic factor and promotes cell migration and invasion in colorectal cancer by directly targeting PTEN.

Authors:  Hai-Bing Sun; Xi Chen; Hong Ji; Tao Wu; Hong-Wei Lu; Yan Zhang; Hua Li; Yi-Ming Li
Journal:  Int J Oncol       Date:  2014-09-22       Impact factor: 5.650

5.  Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc.

Authors:  Y Liu; X Li; S Zhu; J-g Zhang; M Yang; Q Qin; S-c Deng; B Wang; K Tian; L Liu; Y Niu; C-y Wang; G Zhao
Journal:  Gene Ther       Date:  2015-04-28       Impact factor: 5.250

6.  Type 5 adenylyl cyclase increases oxidative stress by transcriptional regulation of manganese superoxide dismutase via the SIRT1/FoxO3a pathway.

Authors:  Lo Lai; Lin Yan; Shumin Gao; Che-Lin Hu; Hui Ge; Amy Davidow; Misun Park; Claudio Bravo; Kousaku Iwatsubo; Yoshihiro Ishikawa; Johan Auwerx; David A Sinclair; Stephen F Vatner; Dorothy E Vatner
Journal:  Circulation       Date:  2013-03-27       Impact factor: 29.690

Review 7.  The Sir2 family of protein deacetylases.

Authors:  Gil Blander; Leonard Guarente
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

Review 8.  Clinically relevant microRNAs in ovarian cancer.

Authors:  Shu Zhang; Zhen Lu; Anna K Unruh; Cristina Ivan; Keith A Baggerly; George A Calin; Zongfang Li; Robert C Bast; Xiao-Feng Le
Journal:  Mol Cancer Res       Date:  2014-10-10       Impact factor: 5.852

9.  SIRT1 is significantly elevated in mouse and human prostate cancer.

Authors:  Derek M Huffman; William E Grizzle; Marcas M Bamman; Jeong-su Kim; Isam A Eltoum; Ada Elgavish; Tim R Nagy
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

10.  MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9.

Authors:  Jingyuan Li; Lijuan Wang; Zongzhi Liu; Chao Zu; Fanfan Xing; Pei Yang; Yongkang Yang; Xiaoqian Dang; Kunzheng Wang
Journal:  Oncotarget       Date:  2015-09-22
View more
  9 in total

1.  SIRT1 and gynecological malignancies (Review).

Authors:  Jiayu Chen; Houzao Chen; Lingya Pan
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

2.  miR-30a suppresses lung cancer progression by targeting SIRT1.

Authors:  Yaowu Guan; Zhongming Rao; Cheng Chen
Journal:  Oncotarget       Date:  2017-12-21

3.  Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation via activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer.

Authors:  Bai-Shun Wan; Ming Cheng; Ling Zhang
Journal:  World J Gastroenterol       Date:  2019-10-28       Impact factor: 5.742

4.  miR-30c Impedes Glioblastoma Cell Proliferation and Migration by Targeting SOX9.

Authors:  Shihui Liu; Xiuxiu Li; Sujing Zhuang
Journal:  Oncol Res       Date:  2018-03-01       Impact factor: 5.574

5.  Identification of keygenes, miRNAs and miRNA-mRNA regulatory pathways for chemotherapy resistance in ovarian cancer.

Authors:  Wenwen Wang; Wenwen Zhang; Yuanjing Hu
Journal:  PeerJ       Date:  2021-11-08       Impact factor: 2.984

Review 6.  Role of different non-coding RNAs as ovarian cancer biomarkers.

Authors:  Anam Beg; Rafat Parveen; Hassan Fouad; M E Yahia; Azza S Hassanein
Journal:  J Ovarian Res       Date:  2022-06-17       Impact factor: 5.506

Review 7.  Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code.

Authors:  Giuseppe Cammarata; Nadia Barraco; Ilaria Giusti; Valerio Gristina; Vincenza Dolo; Simona Taverna
Journal:  Cancers (Basel)       Date:  2022-07-13       Impact factor: 6.575

8.  The plasma peptides of ovarian cancer.

Authors:  Jaimie Dufresne; Pete Bowden; Thanusi Thavarajah; Angelique Florentinus-Mefailoski; Zhuo Zhen Chen; Monika Tucholska; Tenzin Norzin; Margaret Truc Ho; Morla Phan; Nargiz Mohamed; Amir Ravandi; Eric Stanton; Arthur S Slutsky; Claudia C Dos Santos; Alexander Romaschin; John C Marshall; Christina Addison; Shawn Malone; Daren Heyland; Philip Scheltens; Joep Killestein; Charlotte E Teunissen; Eleftherios P Diamandis; K W Michael Siu; John G Marshall
Journal:  Clin Proteomics       Date:  2018-12-21       Impact factor: 3.988

Review 9.  The Role of microRNAs in Epithelial Ovarian Cancer Metastasis.

Authors:  Vu Hong Loan Nguyen; Chenyang Yue; Kevin Y Du; Mohamed Salem; Jacob O'Brien; Chun Peng
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.